PT807125E - Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase - Google Patents

Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase

Info

Publication number
PT807125E
PT807125E PT96939805T PT96939805T PT807125E PT 807125 E PT807125 E PT 807125E PT 96939805 T PT96939805 T PT 96939805T PT 96939805 T PT96939805 T PT 96939805T PT 807125 E PT807125 E PT 807125E
Authority
PT
Portugal
Prior art keywords
psoriasis
monoclonal antibodies
diagnosis
treatment
clinical
Prior art date
Application number
PT96939805T
Other languages
English (en)
Portuguese (pt)
Inventor
Montero Casimiro Jose Enrique
Lombardero Valladares Josefa
Perez Rodriguez Rolando
Sierra Blazquez Patricia
Tormo Bravo Blanca Rosa
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PT807125E publication Critical patent/PT807125E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT96939805T 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase PT807125E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Publications (1)

Publication Number Publication Date
PT807125E true PT807125E (pt) 2005-03-31

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96939805T PT807125E (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase

Country Status (15)

Country Link
US (1) US6572857B1 (enExample)
EP (1) EP0807125B1 (enExample)
JP (1) JP4113929B2 (enExample)
KR (1) KR100533854B1 (enExample)
CN (1) CN1222540C (enExample)
AT (1) ATE280783T1 (enExample)
AU (1) AU722882B2 (enExample)
BR (1) BRPI9607171B1 (enExample)
CA (1) CA2210751C (enExample)
CU (1) CU22584A1 (enExample)
DE (1) DE69633717T2 (enExample)
DK (1) DK0807125T3 (enExample)
ES (1) ES2231826T3 (enExample)
PT (1) PT807125E (enExample)
WO (1) WO1997019111A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
EP1597275B1 (en) 2003-02-24 2010-08-18 Institut Pasteur Use of the Chlamydia pneumoniae CPn0104 polypeptide or antibodies thereto to diagnose Chlamydia infections
MY154819A (en) * 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
NZ578635A (en) * 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
EP3345925A3 (en) * 2010-07-15 2018-09-26 Adheron Therapeutics, Inc. Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2726879B1 (en) 2011-07-01 2022-10-19 Beckman Coulter, Inc. Requlatory t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
WO2019169015A1 (en) 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
ES3061216T3 (en) 2018-06-29 2026-03-31 Hope City Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
WO2020176682A1 (en) 2019-02-26 2020-09-03 Equillium, Inc. Anti-cd6 antibody compositions and methods for treating lupus
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
AU2022344418A1 (en) 2021-09-08 2024-04-04 Centro De Inmunologia Molecular Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723437A (en) * 1993-11-02 1998-03-03 Duke University CD6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
WO1997019111A3 (es) 1998-02-12
CU22584A1 (es) 1999-11-03
CA2210751C (en) 2007-01-30
EP0807125B1 (en) 2004-10-27
JPH11506017A (ja) 1999-06-02
DE69633717T2 (de) 2006-02-02
ATE280783T1 (de) 2004-11-15
DK0807125T3 (da) 2005-03-14
US6572857B1 (en) 2003-06-03
KR100533854B1 (ko) 2006-09-20
CN1175957A (zh) 1998-03-11
KR19980701502A (ko) 1998-05-15
AU7690596A (en) 1997-06-11
MX9705445A (es) 1998-06-30
CA2210751A1 (en) 1997-05-29
BRPI9607171B1 (pt) 2016-07-19
ES2231826T3 (es) 2005-05-16
WO1997019111A2 (es) 1997-05-29
DE69633717D1 (de) 2004-12-02
JP4113929B2 (ja) 2008-07-09
AU722882B2 (en) 2000-08-10
CN1222540C (zh) 2005-10-12
EP0807125A2 (en) 1997-11-19
BR9607171A (pt) 1997-11-11

Similar Documents

Publication Publication Date Title
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ATE192457T1 (de) Trivalent monospezifische antigen-bindende proteine
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
ATE232902T1 (de) Anti-egfr einkettige fvs und anti-egfr antikoerper
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE85652T1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
DE68925226D1 (de) Monoklonale Antikörper
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
BR0210648A (pt) Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
ATE291620T1 (de) Mammakarzinom-assoziiertes gen